PMID: 24603446
Previous studies that explored the effects of larger peptide GLP-1s such as semaglutide in the brain have found that they suppress hunger-driven eating by engaging networks in the hypothalamus and hindbrain
Baseline and ongoing laboratory monitoring should include: Glucose parameters : A1C and fasting glucose at baseline, 3 months, and every 3 months thereafter until stable, then potentially less frequently per ADA guidelines
Clearer communication about the effectiveness of the strategy, and the continued need for living donors, may be the best way forward, the authors conclude
Secondary outcomes included changes in waist circumference, lipid profile, liver enzymes, pancreatic enzymes, HbA1c, insulin resistance, and adverse events